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2Abstract
A large number of placebo-controlled studies have shown that vitamin C supplementation
alleviates the symptoms of the common cold, but widespread skepticism that vitamin C
could have any significant effect remains. One of the most influential common cold
studies, published in 1975, was carried out by Thomas Karlowski  et al. at the National
Institutes of Health. Their placebo consisted of lactose, which can easily be distinguished
from ascorbic acid by taste. Karlowski  et al. found a 17% decrease in the duration of cold
episodes in the group administered vitamin C (6 g/day); however, they suggested that the
decrease was entirely due to the placebo effect. In this article it will be shown that the
placebo effect is not a valid explanation for the results of the Karlowski study, as it is
inconsistent with their results. This is an important conclusion for two reasons. First, the
placebo explanation becomes even more unreasonable as regards the reported benefits
found in several other studies with valid placebo tablets. Second, as the results from the
Karlowski study are not due to the placebo effect, their results can be used to assess the
quantitative effects of vitamin C supplementation. The most important conclusions from
Karlowski's study are that therapeutic vitamin C supplementation during a common cold
episode appears to be as effective as regular supplementation, and that there appears to be
linear dose dependency at least up to 6 g/day. These findings suggest that large therapeutic
vitamin C doses might alleviate the symptoms of the common cold substantially.
Introduction
Vitamin C supplementation has frequently been suggested for the treatment of the common
cold [1-11], which is among the most frequent causes of visits to physicians and of
absenteeism [12]. Gram doses of vitamin C per day have been found to be essentially
harmless even with long-term usage [13,14]. Therefore it appears worthwhile to examine
thoroughly whether vitamin C supplementation does have beneficial effects during
common cold episodes.
In 1975 Thomas Karlowski et al. published a vitamin C-common cold study [15] that
received widespread attention for two particular reasons. First, as the study was carried out
at the National Institutes of Health (NIH) and the subjects of the study were employees of
the NIH, the social background gave the study considerable influence. Second, the study
was published in the Journal of the American Medical Association (JAMA), a respected
journal with a very wide circulation. However, technically the Karlowski study is not
among the best, since their placebo consisted of lactose, which is sweet, whereas they used
ascorbic acid in the vitamin C tablets, so that it is possible that some of the subjects
identified the tablets by taste. In fact, it was concluded by the authors that the results were
entirely due to the placebo effect: "the effects demonstrated might be explained equally
well by a break in the double blind" [15], and this was also forcefully emphasized in a
concurrent review [16] written by Thomas Chalmers, one of the members of the Karlowski
team. The "placebo explanation" of Karlowski's results has been reiterated in a major
textbook on infectious diseases [12] and in several other commentaries on the vitamin C-
common cold relationship [17-19]. The Karlowski study even led to a suggestion that the
placebo effect could be a general explanation for benefits observed in other common cold
studies [16]. The latter proposal is simply unfounded, since in a large number of studies it
has been explicitly confirmed that the placebo and vitamin C tablets were indistinguishable
[20-24].
3Although the placebo was improperly selected in the Karlowski study, there are no other
grave shortcomings in the study. Moreover, the study contains certain important features.
The Karlowski study was reasonably large, having 190 subjects with a total of 249 cold
episodes, and the vitamin C doses used were among the highest so far (3–6 g/day).
Biologically, the most important features of the study are the direct comparison of the
therapeutic and prophylactic methods of supplementation and the comparison of two
different dosages (3 and 6 g/day) in the same study. Therefore, if the "placebo explanation"
favored by the authors [15, 16] can be confidently rejected, the results of the Karlowski
study can be used to compare therapeutic versus regular supplementation and to analyze
the dose dependency up to 6 g/day.
INTERPRETATION OF KARLOWSKI’S RESULTS
The Basis of the "Placebo Explanation"
The Karlowski study [15] lasted for 9 months and there were four treatment groups in the
study (Table 1). Each subject received two kinds of tablets: prophylactic (each day) and
therapeutic (5 days during a cold). Ascorbic acid (3 g/day) was used in the active tablets
and lactose was used in the placebo tablets, a different combination being administered to
each of the four groups. The mean duration of cold episodes in each of the study groups is
shown in Table 1. After the Karlowski study was completed the subjects were asked in a
questionnaire to guess which tablets they were given [15]. In the case of prophylactic
tablets there was very strong bias in favor of correct answers (Table 2; p < 10–6). In
contrast, there was barely any evidence of bias in the case of therapeutic tablets (Table 3; p
= 0.27).
Karlowski et al. assumed that all subjects giving a correct answer genuinely identified
the treatment, without taking into consideration that there also were pure guesses among
the correct answers. Thus, Karlowski et al. assumed that 79 (= 40 + 39) subjects "knew"
whether they were given vitamin C or placebo as prophylactic tablets (Table 2; cf Table 4
in [15]). However, this is most probably an erroneous assumption. In the case of the
prophylactic tablets, 12% of subjects gave the wrong answer both for placebo and vitamin
C (Table 2). Assuming that the subjects gave a correct answer purely as a guess with a
similar frequency, we may estimate that 56 (= 28 + 28) subjects "really knew" their
prophylactic tablets. Thus, of all subjects about 29% (56/190) genuinely recognized the
prophylactic tablets at the end of the study.
For the therapeutic tablets, there was no substantial evidence that the distribution of
answers was not due to pure chance (Table 3). However, assuming that there is actual but
slight bias, we may use the number of wrong answers (16%) to estimate the number of
subjects genuinely recognizing their tablets. We may estimate that 11 (= 9 + 2) subjects
"really knew" the therapeutic tablets, which is considerably lower than the estimate derived
on the basis of Karlowski's rationalization (32 = 20 + 12). Thus, of all subjects receiving
therapeutic tablets about 8% (11/132) genuinely recognized the type of therapeutic tablet at
the end of the study.
 Obviously, it is impossible to know purely on the basis of a correct answer which of the
subjects genuinely knew and which simply guessed the correct answer. There appears to be
no sound basis for treating the two groups as one homogeneous group. Nevertheless,
Karlowski et al. used "correct answer" as a surrogate for "knowing" and designated the
subjects giving correct answers as "unblinded" [15]. There were dramatic differences
between the vitamin C and placebo groups in the "unblinded" subjects (Table 4), far
4greater than in the total population (Table 1). Karlowski et al. also formed a group of
"blinded" subjects, apparently from those who guessed incorrectly and those who made no
guess, but the selection criteria for the "blinded" group were not explicitly described. In the
"blinded" subjects there were no differences among the four treatment groups (Table 4).
This led Karlowski et al. [15] and Chalmers [16] to infer that it was "knowing the
treatment", i.e., the placebo effect, that caused the large differences in the "unblinded"
subjects (Table 4) and the moderate differences in the whole study population (Table 1).
Table 1: Results of the Karlowski study: Duration of cold episodes
(in days) in four treatment groupsa
Therapeutic tablets
(5 days during an episode)
Prophylactic
tablets
(each day)
Placebo
Vitamin C
 (3 g/day)
Difference
 (days)
Placebo 7.14±0.46 6.46±0.39 -0.68±0.61
(65) (56)
#0 #1
Mean: -0.735±0.446
(t = 1.65, p = 0.1)
Vitamin C 6.71±0.53 5.92±0.40 -0.79±0.65
(52) (76)
#2 #3
Difference (days) -0.43 -0.54 -1.22±0.61
Mean: -0.485 (t = 2.01, p = 0.05)
a Prophylactic tablets were administered each day and therapeutic tablets were
administered for 5 days during cold episodes. The outcome is the mean
duration of episodes in days (± standard error); data are from [15,16,25]. The
number of colds in each group is shown in parentheses and the numbers used
to designate the study groups [15] are marked below the mean duration of cold
episodes (#). The differences and the statistical significance of the differences
were calculated by the present author, since Karlowski et al. did not report the
results from their statistical analysis, as they assumed that the differences
between groups were purely due to the placebo effect [15]. The p values are
two-tailed.
5Table 2: Prophylactic tablets: Guessing the treatment
Answer
Actual drug Placebo Vitamin C
Did not
guess Total subjects
Placebo 39 11(12%)a 39 89
Vitamin C 12(12%)a 40 49 101
?2=28.6b, p < 10-6
Subjects divided into groups on the basis of "guessing" and "knowing":
"Guessing" "Knowing"
Actual drug Placebo Vitamin C Placebo Vitamin C
Placebo 11c 11 28 —
Vitamin C 12 12c — 28
a Percentage of subjects receiving the actual drug.
b ?2 test with Yates' correction. Karlowski et al. [15] obtained the same ?2  value (28.6),
indicating that they also used Yates' correction in analyzing the answers as to the
prophylactic tablets. However, in the case of the therapeutic tablets Karlowski et al. did not
use Yates' correction (cf. Table 3).
c Correct guesses have been estimated from the number of wrong answers.
Table 3: Therapeutic tablets: Guessing the treatment
Answer
Actual drug Placebo Vitamin C
Did not
guess Total subjects
Placebo 12 10(16%)a 40 62
Vitamin C 11 (16%)a 20 39 70
?2=1.21b, p = 0.27 (2-tailed)
Subjects divided into groups on the basis of "guessing" and "knowing":
"Guessing" "Knowing"
Actual drug Placebo Vitamin C Placebo Vitamin C
Placebo 10c 10 2 —
Vitamin C 11 11c — 9
a Percentage of subjects receiving the actual drug,
b ?2 test with Yates' correction, Karlowski et al. did not use Yates' correction in
analyzing the answers as to the therapeutic tablets. Karlowski et al. gave ?2 = 1.8 [15],
but the correct ?2 value is 1.90 without Yates' correction, and the reason for the slight
discrepancy is not obvious. In the case of the prophylactic tablets Karlowski et al. did
use Yates' correction (cf. Table 2).
c Correct guesses have been estimated from the number of wrong answers.
6Problems with the "Placebo Explanation"
There are two questions relevant to Karlowski's and Chalmers's "placebo explanation."
First, is the "placebo explanation" consistent with the observed results? Second, is there
evidence that identification of the tablets actually resulted from tasting?
As regards the first question, the results (Tables 1 and 4) are not consistent with the
"placebo explanation." In the study there were some 11 subjects who "really knew" their
therapeutic tablets and some 56 subjects who "really knew" their prophylactic tablets
(Tables 2 and 3). Thus, assuming that the results are caused by the placebo effect, we
should expect that the prophylactic tablets would show much greater effect than the
therapeutic tablets. However, prophylactic tablets were 34% less effective in all study
subjects (0.485/0.735; Table 1) and 75% less effective in "unblinded" subjects. (0.75/3.05;
Table 4) than the therapeutic tablets. The greater benefit from the therapeutic tablets is
inconsistent with the "placebo explanation," since there is statistically no valid evidence
that any subjects really knew the therapeutic tablets (p = 0.27), and only a few subjects, at
most, did know (8%).  Moreover, the selection criteria for the "unblinded" group were  not
explicitly described, although one may assume that it was composed of subjects who gave
a correct answer to the query about both the therapeutic and prophylactic tablets. Neither
was the number of subjects in the "unblinded" group revealed [15]. There were 52 cold
episodes among the "unblinded" group (Table 4), and on average there were 1.3 colds per
subject in the study [15]. Thus we may infer that there were some 40 subjects in the
"unblinded" group. However, there were only some 11 subjects who "really knew" the
therapeutic tablets in the entire study population (Table 3). If the placebo effect in these 11
subjects was responsible for the average of 3.05 days in the shortening of episodes by the
therapeutic tablets in the entire "unblinded" group (Table 4), the "mean placebo effect"
should be some 10 days among the 11 subjects who genuinely knew the therapeutic tablets.
This provides a second reason why the "placebo explanation" leads to untenable logical
consequences.
As regards the "placebo explanation" of Karlowski's results, it is not even sufficient to
assume that realizing that one had been given ascorbic acid caused a decrease in the
duration of symptoms. In fact, one must assume that the realization that one had been
given lactose caused an even stronger psychological effect (Table 4). The colds were much
longer in group 0 (double-lactose) of the "unblinded" subjects (8.6 days) when compared
to the "blinded" (6.3 days). Thus, Karlowski et al. should more properly have discussed the
"antiplacebo effect" of lactose as the major explanation of their results, since the
"maximum effect" of lactose tablets was greater than the "maximum effect" of ascorbic
acid tablets (2.3 days and –1.7 days, respectively; Table 4).
Furthermore, there is a problem with the division of subjects into the two categories of
"blinded" and "unblinded" as it was done by Karlowski et al. These two groups contained
144 (= 92 + 52) cold episodes (Table 4), whereas there were 249 episodes among all
subjects (Table 1). Thus there is a group of missing persons with a total of 105 cold
episodes (Table 5); in other words, nearly half of all observed episodes are missing from
Karlowski's subgroup analysis. In the missing group the mean duration of colds was 7.2
days in group 0 (double-placebo) and 5.8 days in group 3 (double-vitamin C). Thus, the
therapeutic effect of the largest vitamin C dose (6 g/day) was greater in the missing group
(–1.4 days; Table 5) than in the whole study population (–1.22 days; Table 1). It is not
clear what Karlowski's explanation for the missing group was, and why it was not shown
along with the data for the two other subgroups.
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“unblinded” and “blinded” groupsa
Treatment
Prophylactic
Placebo Vitamin C
Difference
(days)
”Unblinded” subjects
Placebo 8.6 4.7 –3.9
(16) (15)
#0 #1
Vitamin C 7.0 4.8 –2.2
(8) (13)
#2 #3
Difference (days) -1.6 +0.1 –3.8
”Blinded” subjects
Placebo 6.3 6.7 +0.4
(30) (18)
Vitamin C 6.4 6.5 +0.1
(14) (30)
Difference (days) +0.1 –0.2 +0.2
Difference between the ”unblinded”
and blinded”subgroups
Placebo +2.3 –2.0
Vitamin C +0.6 –1.7
a The data for the "blinded" and "unblinded" subjects are from [15,16,25].
The outcome is the mean duration of episodes in days. The number of
colds in each group is shown in parentheses and the number of the study
group is marked below the mean duration of cold episodes.
8Table 5. Colds missing from Karlowski's subgroup analysis: duration of cold episodes
(in days) in the missing groupa
Treatment
Prophylactic
Placebo Vitamin C
Difference
Placebo 7.2 7.4 +0.2
(19) (23)
#0 #1
Vitamin C 6.8 5.8 –1.0
(30) (33)
#2 #3
Difference (days) –0.4 –1.6 –1.4
a The data were calculated from the number and the mean duration of cold
episodes in the "unblinded" and "blinded" groups (Table 4) and all subjects
(Table 1). The outcome is the mean duration of episodes in days. The
number of colds in each group is shown in parentheses and the number of
the study group is marked below the mean duration of cold episodes.
As regards the second question, whether the tablets were identified by taste, the
distribution of subjects who genuinely knew their therapeutic tablet (Table 3) is not
consistent with the suggestion that tablets were identified by taste. If a subject found the
tablet acidic he or she could not infer that the tablet contained ascorbic acid and not, for
example, citric acid, which has been used in several other studies as a placebo [21-24]. By
contrast, if a subject found the tablet sweet, he or she could infer that the tablet was not
made of ascorbic acid or sodium ascorbate. Thus, in Karlowski's study the subjects could
infer by taste that they were receiving placebo but not that they were receiving vitamin C.
In the case of the therapeutic tablets the distribution of "genuinely knowing" subjects is,
however, the opposite (Table 3). Thus the data do not support the notion that the
therapeutic tablets were identified by taste. Neither do Karlowski et al. provide any explicit
data from their questionnaire indicating that the identification of the therapeutic tablets
would have been by taste [15,16,25].
In the case of the prophylactic tablets the distribution of data  is not quite inconsistent
with tasting as one important source of information (Table 2). Since the study lasted for 9
months and the subjects took two prophylactic tablets three times per day, it seems quite
obvious that several subjects tasted their prophylactic tablets during such a lengthy trial. In
a parallel study report [25] the Karlowski group provided direct data on the tasting of
prophylactic tablets as revealed by the questionnaire, but this paper was not referred to in
the original JAMA report [15] or in Chalmers's review [16]. It can be estimated that of the
76 among the 190 study subjects who tasted the prophylactic tablets [25] only 60% (46/76)
"really knew" the correct tablet, consistent with the problems of inference from taste as
noted above. From Karlowski's data it can also be calculated that 18% (10/56) of the
9subjects that "really knew" the prophylactic tablet had not tasted the tablets, indicating that
there were other ways of identifying the type of prophylactic tablet [25]. No data were
revealed about tasting the therapeutic tablets [25].
Finally, the criteria used for selecting subjects for the "blinded" and "unblinded" groups
do not seem logical. As the authors wanted to test the hypothesis that "believing" one was
given vitamin C or placebo could explain the results [15], they should not have separated
the subjects with "incorrect answers" from those with "correct answers." The
psychological effects should be identical when the subject believes in his or her answer,
irrespective of whether the answer is true or false. Thus, Karlowski's separation of subjects
with incorrect and correct answers into different subgroups appears questionable, as the
purpose was to analyze the role of psychological effects specifically.
Thus, Karlowski's [15] and Chalmers's [16] "placebo explanation" is based on
insufficient consideration of the consistency of the "placebo explanation" with the actual
data from their own study. The greater therapeutic effect from the therapeutic tablets,
which were not "known" to the subjects, is a strong argument against the placebo effect as
the major explanation for the reported findings of the Karlowski study.
AN ALTERNATIVE EXPLANATION OF THE BIAS  IN "KNOWING":
INFERENCE FROM THE SUBJECTIVE OBSERVATION
There has been an enduring popular belief that vitamin C supplements alleviate the
symptoms of the common cold, making it possible that several subjects inferred the
vitamin C treatment from the subjective feeling that the cold symptoms were mild.
Similarly, the feeling that the symptoms were prolonged may have led a subject to infer
that vitamin C was not being given, but rather placebo. The proposed explanation appears
to explain the large bias in the distribution of subjects who "really knew" their therapeutic
tablets (Table 3), since the subjective observation that symptoms are milder than usual
may lead to the inference that the "active" drug has been given, whereas if there is no
difference compared to previous colds one cannot confidently infer placebo, since the
"active" drug could simply be ineffective.
In some studies [20-24] the difference in the duration of cold  episodes between the
placebo and vitamin C groups has been so great (30–70% decrease with the vitamin) that it
would be no surprise if vitamin C tablets could be correctly identified by some persons on
the basis of subjective observation. Furthermore, when Asfora initiated a double-blind
study to test the effects of 6 g/day of vitamin C on the common cold, subjects receiving the
vitamin could be identified by their clinical progress [26]. With such data it appears
unreasonable to assume that tasting was the only possible means to infer the contents of
tablets in the Karlowski study.
In fact, the "knowledge inferred from the subjective observation" explanation is also
directly supported by the data from the Karlowski study. Among subjects who had not
tasted their prophylactic placebo tablets, those who had colds during the study tended to
suspect that they were being given placebo, whereas those who did not have colds tended
to suspect they were being given vitamin C (p < 0.05) [25]. A similar kind of inference
can apparently be made from the duration of colds, but this was not considered by
Karlowski et al. [15,25]. The alternative explanation is briefly mentioned but not properly
analyzed in the JAMA report [15] and in the parallel study report [25], the "placebo
explanation" being strongly favored in both papers. However, the alternative explanation is
not mentioned at all in Chalmers's review [16].
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Evidently the only logical possibility of using the "placebo explanation" is in explaining
the difference between the prophylactic and therapeutic vitamin C, since the former were
correctly identified by many subjects but the latter only by a few. Since the prophylactic
tables were less effective, one should assume that there was a small "antiplacebo" effect
induced by prophylactic vitamin C tablets to explain the smaller benefit compared to the
therapeutic tablets (Table 1). Nevertheless, statistical variation or a true physiological
difference between the two methods of supplementation would seem more reasonable
explanations of this rather small difference.
CONCLUSIONS
The division of subjects into subgroups according to guessing the treatment, as was done in
Karlowski's study, may easily result in misleading conclusions. For example, if penicillin
is given to patients with bacterial infections the treatment may be beneficial for certain
patients and ineffective for the rest. If we exclude from the analysis patients who, because
of the subjective feeling of benefit, correctly answer a query after the study as to the tablets
administered ("unblinded" subjects), we could end up with a group of patients infected
with penicillin-resistant bacteria ("blinded" subjects). An analysis of the "blinded"
subgroup of patients would lead to an entirely false impression of the usefulness of
penicillin in patients infected with penicillin-sensitive bacteria. Thus, one should be very
cautious, as Karlowski et al. were not, when dividing subjects into subgroups on the basis
of variables that may be associated with a possibly real effect and guessing the treatment is
obviously one of such variables. Obviously, the validity of the placebo should be examined
before the study [23], and not after the completion of the study as was done by Karlowski
et al.
The rejection of Karlowski's [15] and Chalmers's [16] "placebo explanation" is important
since it validates the use of Karlowski's results in the quantitative estimation of the effects
of vitamin C. Karlowski's results are important in three particular respects.
First, the comparison of the therapeutic and prophylactic methods of supplementation in
the same study provides an estimate of their relative effects. Essentially all of the placebo
controlled studies have used prophylactic supplementation [20-23], and it is an important
question to what extent their results can be used as estimates of the benefit of therapeutic
supplementation. From Karlowski's results it appears that with a fixed dose, a proper
therapeutic supplementation can yield approximately as great a benefit as prophylactic
supplementation (Table 1). Another therapeutic study carried out by Anderson et al. using
1–1.5 g/day of vitamin C for 5 days during cold episodes found a 25% decrease in "days
confined indoors" [24]. In a prophylactic study by Anderson et al. [23] with 1 g of vitamin
C per day, given regularly (3 g/day extra during colds), the decrease in "days confined
indoors" per episode was 21%, which matches quite well with the results from the
therapeutic study by the same group. Thus, Karlowski's study and Anderson's two studies
suggest that the regular supplementation studies may be used to estimate the benefits from
appropriate therapeutic vitamin C supplementation.
Second, Karlowski's results indicate that there is linear dose dependency even with high
intakes of up to 6 g/day (Table 1), and it appears possible that still higher doses might
produce even greater effects. The largest dose (6 g/day) decreased the duration of colds by
17% and linear extrapolation suggests that 35 g/day would totally suppress common cold
symptoms. Even though such a crude extrapolation must be regarded with great caution, it
is noteworthy that Cathcart has suggested that the optimum dose of vitamin C in the
treatment of the common cold would be over 30 g/day [7], quite consistent with this
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extrapolation. Thus, it seems probable that the vitamin C doses used in the common cold
studies (?6 g/day; [15,20-26]) have not been large enough to reveal the maximum effects
of vitamin C supplementation.
Third, the observed effect is quite small in Karlowski's study when considering the fairly
large doses used. In several other studies smaller doses have produced greater effects [20-
24]. One possible explanation for the rather small benefit is the character of the subjects
used. Anderson et al. [23,24] found that vitamin C supplementation was much more
beneficial for subjects with a low daily intake of fruit juices (a major source of vitamin C).
In their first study Anderson et al. [23] found that vitamin C (1–4 g/day) decreased the
"days confined to house" per person by 48% in subjects with a low intake of fruit juices
(<4 oz/day), but only by 22% in subjects with a higher intake of fruit juices. It seems
probable that the medically aware employees of the NIH have on average a much healthier
diet than the general population and, for example, eat more fruits and fruit juices. Thus,
Karlowski's study with employees of the NIH may underestimate the potential benefits of
similar vitamin C doses for subjects with a diet more typical of the general population or
for subjects with a decidedly poor diet.
Karlowski et al. considered that the effect, even if real, is in  any case clinically
insignificant, and concluded that "it does not seem worthwhile to take two capsules or
tablets three times a day for the rest of one's life to achieve such a small and equivocal
benefit" [15]. However, in concluding this they missed several important findings in their
own study, which are discussed above. First, they could have noted that three times a day
during a cold episode is much more feasible and much less costly than "three times a day
for the rest of one's life," and their own results suggest the benefit from therapeutic
supplementation is at least as great as from regular supplementation. Second, as there was
a linear dose dependency in their own results they could have noted that therapeutic doses
larger than 6 g/day would probably have decreased the duration of episodes by over 17%.
Third, they cited Anderson's first paper [23], reporting that vitamin C supplementation is
much more beneficial for subjects with low fruit juice intake, and consequently could have
noted that their own subjects were probably not the kinds of subjects who would derive the
greatest benefit from vitamin C supplementation.
On the basis of published placebo controlled studies it is obvious that vitamin C
supplementation decreases the duration and severity of common cold episodes [11,15,20-
26]. However, there are numerous open questions as regards the optimum dose, the best
methods of treatment, the maximum therapeutic effects, etc. It also appears likely that the
effects of vitamin C supplementation vary greatly among different subgroups of people.
For example, Anderson et al. found in two studies that vitamin C supplementation was
more beneficial for subjects with low dietary vitamin C intake and for subjects who were
in contact with young children [23,24]. They also found other differences between
subgroups, but those were not as consistent. Thus, it would appear more relevant to ask
which are the subgroups that would benefit most from vitamin C supplementation, rather
than to ask whether a fixed numerical value found, for example, with employees of the
NIH is great enough to validate regular vitamin C supplementation for the general
population. It appears that an important reason preventing proper conclusions from the
vitamin C-common cold studies has been the preconception that vitamin C cannot affect
the common cold. In addition to Karlowski's analysis of their own results [15], the bias is
apparent in Chalmers's concurrent review [16], in which data conflicting with original
published results were used and the analysis of results was carried out improperly,
rendering the assessment of the effect meaningless [22]. Anderson et al. [23] explicitly
noted that when planning their first study they were skeptical that vitamin C could have
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any effects on the common cold, and therefore they tried to make as large and as careful a
study as possible so that critics could not argue that a negative result might be due to the
technical shortcomings of the study. Their placebo consisted of citric acid and in a pilot
trial the placebo and ascorbic acid tablets could not be distinguished. The conclusion that
vitamin C does have physiological effects on the common cold symptoms seemed
inescapable [23]. Pauling, who enthusiastically proposed that vitamin C supplements could
help against the common cold [9], complained that many of his critics had not read either
his texts or the original reports and gave several detailed examples to support his case [11].
The obvious shortcomings in the Karlowski and Chalmers "placebo explanation" give
further support to Pauling's allegation that many people have not analyzed the available
data thoroughly and objectively, although they maintain strongly held views.
The nutritional recommendation for vitamin C, 60 mg/day [27], is not based on clinical
or epidemiological studies suggesting that such a dose would be the best for health in the
long term; rather, the only criterion is that such a dose prevents overt scurvy with an ample
safety margin [11,27-33]. Vitamin C participates in a number of enzymatic and
nonenzymatic reactions [20,32-35], and consequently it is quite possible that the
physiological effects of the vitamin are not limited to the prevention of overt scurvy. As
regards the effects of vitamin C on the immune system in particular it is noteworthy that
very high concentrations of vitamin C are found in phagocytes and lymphocytes [36,37]. It
appears that vitamin C may provide protection against reactive oxygen species produced in
an infection; also, it may increase the proliferative responses of T lymphocytes and the
production of interferon (for references see [20,22]). Published intervention studies [15,20-
26] suggest that it would be worthwhile to carry out further controlled studies to assess the
effects of large therapeutic vitamin C doses on the symptoms of the common cold.
The author is grateful to Dr Pekka Louhiala for his critical reading of the manuscript.
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